Search

everythinglearnresearchcommunity

for

Search:↓

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The user has been using finasteride for two years without results and recently started a new routine involving derma stamping, retinol, and minoxidil, which seems to show progress. The user microneedles about half the week and uses L’Oréal night serum for retinol.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

An 18-year-old started using finasteride for hair loss, already seeing results from minoxidil but experiencing shedding. They also use castor, rosemary, and peppermint oils, dermarolling, and are questioning the need for Nizoral while on finasteride.

User applied Xyon fin topical gel daily, used Augstinus Bader shampoo, conditioner, and scalp treatment, and applied argan oil twice a week. No Minoxidil, no dermarolling, and no side effects were reported.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

Minoxidil causes dryness, and adding an emollient might help. The foam version is suggested to reduce dryness.

Oral finasteride is recommended over topical finasteride for men in the Indian subcontinent, with no reported side effects. Minoxidil and dermarolling are also suggested, while dietary supplements and topical finasteride are deemed less effective.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.